Literature DB >> 32442321

AutoPVS1: An automatic classification tool for PVS1 interpretation of null variants.

Jiale Xiang1, Jiguang Peng1, Samantha Baxter2, Zhiyu Peng1.   

Abstract

Null variants are prevalent within the human genome, and their accurate interpretation is critical for clinical management. In 2018, the ClinGen Sequence Variant Interpretation (SVI) Working Group refined the only criterion with a very strong pathogenicity rating (PVS1). To streamline PVS1 interpretation, we have developed an automatic classification tool with a graphical user interface called AutoPVS1. The performance of AutoPVS1 was assessed using 56 variants manually curated by the ClinGen's SVI Working Group; it achieved an interpretation concordance of 93% (52/56). A further analysis of 28,586 putative loss-of-function variants by AutoPVS1 demonstrated that at least 27.7% of them do not reach a very strong strength level, 17.5% because of variant-specific issues and 10.2% due to disease mechanism considerations. Notably, 41.0% (1,936/4,717) of splicing variants were assigned a decreased preliminary PVS1 strength level, a significantly greater fraction than in frameshift variants (13.2%) and nonsense variants (10.8%). Our results reinforce the necessity of considering variant-specific issues and disease mechanisms in variant interpretation and demonstrate that AutoPVS1 meets an urgent need by enabling biocurators to easily assign accurate, reliable and reproducible PVS1 strength levels in the process of variant interpretation. AutoPVS1 is publicly available at http://autopvs1.genetics.bgi.com/.
© 2020 Wiley Periodicals LLC.

Entities:  

Keywords:  ClinGen; PVS1; null variants; variant interpretation

Year:  2020        PMID: 32442321     DOI: 10.1002/humu.24051

Source DB:  PubMed          Journal:  Hum Mutat        ISSN: 1059-7794            Impact factor:   4.878


  7 in total

1.  Comprehensive interpretation of single-nucleotide substitutions in GJB2 reveals the genetic and phenotypic landscape of GJB2-related hearing loss.

Authors:  Jiale Xiang; Xiangzhong Sun; Nana Song; Sathishkumar Ramaswamy; Ahmad N Abou Tayoun; Zhiyu Peng
Journal:  Hum Genet       Date:  2022-09-01       Impact factor: 5.881

2.  Clinical Interpretation of Sequence Variants.

Authors:  Junyu Zhang; Yanyi Yao; Haixian He; Jun Shen
Journal:  Curr Protoc Hum Genet       Date:  2020-06

3.  Yield of array-CGH analysis in Tunisian children with autism spectrum disorder.

Authors:  Fethia Chehbani; Pasquale Tomaiuolo; Chiara Picinelli; Marco Baccarin; Paola Castronovo; Maria Luisa Scattoni; Naoufel Gaddour; Antonio M Persico
Journal:  Mol Genet Genomic Med       Date:  2022-06-27       Impact factor: 2.473

4.  Novel Germline PHD2 Variant in a Metastatic Pheochromocytoma and Chronic Myeloid Leukemia, but in the Absence of Polycythemia.

Authors:  Aldesia Provenzano; Massimiliano Chetta; Giuseppina De Filpo; Giulia Cantini; Andrea La Barbera; Gabriella Nesi; Raffaella Santi; Serena Martinelli; Elena Rapizzi; Michaela Luconi; Mario Maggi; Massimo Mannelli; Tonino Ercolino; Letizia Canu
Journal:  Medicina (Kaunas)       Date:  2022-08-17       Impact factor: 2.948

5.  Non-Invasive Detection of a De Novo Frameshift Variant of STAG2 in a Female Fetus: Escape Genes Influence the Manifestation of X-Linked Diseases in Females.

Authors:  Aldesia Provenzano; Andrea La Barbera; Francesco Lai; Andrea Perra; Antonio Farina; Ettore Cariati; Orsetta Zuffardi; Sabrina Giglio
Journal:  J Clin Med       Date:  2022-07-19       Impact factor: 4.964

6.  Case report: Phenotype expansion and analysis of TRIO and CNKSR2 variations.

Authors:  Yuefang Liu; Zhe Liang; Weili Cai; Qixiang Shao; Qiong Pan
Journal:  Front Neurol       Date:  2022-08-29       Impact factor: 4.086

7.  Variant Selection and Interpretation: An Example of Modified VarSome Classifier of ACMG Guidelines in the Diagnostic Setting.

Authors:  Francesca Cristofoli; Elisa Sorrentino; Giulia Guerri; Roberta Miotto; Roberta Romanelli; Alessandra Zulian; Stefano Cecchin; Stefano Paolacci; Jan Miertus; Matteo Bertelli; Paolo Enrico Maltese; Pietro Chiurazzi; Liborio Stuppia; Marco Castori; Giuseppe Marceddu
Journal:  Genes (Basel)       Date:  2021-11-25       Impact factor: 4.096

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.